NCT05162443Approved For Marketing不适用
Expanded Access Use of Adagrasib (MRTX849) for the Treatment of Patients With Advanced Solid Tumors With a KRAS G12C Mutation
Bristol-Myers Squibb11 个研究点 分布在 1 个国家开始时间: 2021年12月17日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- Approved For Marketing
- 发起方
- 试验地点
- 11
研究概览
简要总结
The objective of this EAP is to provide expanded access of adagrasib (MRTX849) to patients with previously treated advanced solid tumors harboring a KRAS G12C mutation.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically confirmed diagnosis of an advanced/metastatic solid tumor
- •Confirmed presence of a KRASG12C mutation
- •Ineligible for an ongoing clinical trial of MRTX849
- •No available or not eligible for standard of care treatment
- •Adequate organ function
- •CNS Metastases (within set parameters) are allowed
- •ECOG performance status of ≤ 2
排除标准
- •History of intestinal disease, inflammatory bowel disease, major gastric surgery, or other gastrointestinal conditions likely to alter absorption of MRTX849 treatment or result in inability to swallow
- •Prior therapy targeting a KRAS G12C mutation
- •Other active cancer
研究者
研究点 (11)
Loading locations...
相似试验
Approved For Marketing
不适用
Expanded Access Program (EAP) for Participants With Advanced Cancers and Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations Who Have Exhausted All Treatment OptionsAdvanced Cancers and FGFR Genetic AlterationsNCT03825484Janssen Scientific Affairs, LLC
Approved For Marketing
不适用
Margetuximab Expanded Access ProgramNCT03133988TerSera Therapeutics LLC
No Longer Available
不适用
Expanded Access Protocol of Verdiperstat in Patients With Multiple System Atrophy (MSA)Multiple System Atrophy (MSA)NCT05086094Biohaven Pharmaceuticals, Inc.
Approved For Marketing
不适用
Pre-Approval Access With Amivantamab (JNJ-61186372) in Participants With Metastatic Non-Small Cell Lung CancerMetastatic Non-Small Cell Lung CancerNCT04599712Janssen Research & Development, LLC
Available
不适用
Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene CiloleucelLarge B-cell LymphomaFollicular LymphomaNCT05776160Kite, A Gilead Company